Adit Ben-Baruch- The Shmunis School of Biomedicine and Cancer Research, The George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel
Introduction – The Long and Winding Road of TNFα in Cancer Therapy
The potent pro-inflammatory cytokine tumor necrosis factor α (TNFα) has been connected to cancer progression and treatment ever since its discovery as a major factor contributing to the anti-tumor activities of Coley’s toxins (1, 2). TNFα cloning in 1984/1985 (3, 4) and of its TNFR1 and TNFR2 receptors in 1990 (5–8) was followed by a spurt of studies demonstrating that TNFα has anti-malignancy activities. The beneficial effects of TNFα were observed in vivo primarily when the cytokine was administered at relatively high concentrations locally and repeatedly; the cytokine inhibited tumor growth by damaging the tumor vasculature and by directly inducing cancer cell killing, at times clearly seen when NF-κB and JNK activation was impaired (3, 9–16). Moreover, TNFα could improve the efficacy of drugs/chemotherapy in cancer treatment, e.g., by promoting blood vessel permeability (16, 17).
In clinical trials (primarily in sarcomas), TNFα was often administered locally, in order to generate high tumor concentration of the cytokine; although these trials have led to tumor regression (to various extents in the different trials), usually they did not have a pronounced ability to induce complete remission (16, 18, 19). To enable local activity of TNFα, antibody-TNFα fusion proteins (immunocytokines) were also assayed, with a relatively good efficacy in mouse cancer models, and in a small cohort of glioblastoma patients (20–23). Other cancer clinical studies have used systemic administration of TNFα, demonstrating low efficiency and giving rise to multiple side effects (15, 24, 25).
In parallel to these findings, other reports have emerged, connecting the presence of TNFα in tumors with pro-malignancy effects, and demonstrating that higher endogenous TNFα expression levels were associated with more advanced disease in cancer patients (2, 26–31). TNFα was found to be expressed in tumors from early stages of disease and on, and its continuous presence contributed to chronic inflammation, considered the Seventh Hallmark of Cancer (31–38). Moreover, the expression of TNFα by tumor cells, leukocytes and stromal cells has led to production of inflammatory chemokines that recruited leukocytes with pro-metastatic effects (26, 28, 31, 35, 38–41). Immune-suppression was also connected to TNFα presence in cancer and studies in animal models have greatly supported its tumor- and metastasis-promoting roles (2, 42–46).
Adding to these observations, numerous studies indicated that TNFα can act directly on cancer cells to promote their pro-metastatic characteristics and functions, including the generation of cancer stem cells, epithelial-to-mesenchymal transition, invasion, resistance to therapy and metabolic changes (27–31, 37, 47–51).
As research in this direction advanced, TNFα has been identified as a most powerful pro-cancer cytokine in many malignancies, suggesting that inhibitors of TNFα and/or its receptors (TNFR) could be applied in cancer treatment, alone or together with other modes of therapy.
The Complexity of the TNFα-TNFR Network – What Is the Road Made of?
In trying to understand the opposing observations on TNFα in cancer, it is important to consider that the TNFα-TNFR network includes many different members, generating intricate interactions that are spatially and temporally regulated, leading to diverse consequences under different conditions.
Many reviews have described in detail the complexity and flexibility of the TNFα-TNFR network [e.g., (27, 52–54)]. In a nutshell, the system is identified by the following characteristics: (1) It includes a soluble and a membrane form of TNFα (mTNFα): while the receptor TNFR1 (p55) binds soluble TNFα and mTNFα, TNFR2 (p75) is fully activated by mTNFα; (2) TNFR1 is constitutively expressed by almost all cells, whereas TNFR2 expression is noted primarily in hematopoietic, endothelial and neuronal cells. (3) TNFα binding to its receptors gives rise to their trimerization, followed by unique signaling patterns of each of the receptors. Following the formation of a core signaling complex and regulation by additional intracellular components/events, TNFR1 can induce cell apoptosis and necroptosis via activation of its death domain; however, under different settings, TNFR1 can lead via activation of the NF-κB, JNK and p38 pathways to transcription of potent pro-inflammatory genes, cell survival, proliferation and motility. TNFR2, on the other hand, ultimately leads to expression of pro-inflammatory genes, cell survival and proliferation by activating canonical and non-canonical NF-κB pathways; (4) TNFR1 and TNFR2 can interact at several levels, including the ability of TNFR2 to promote the pro-apoptotic activities of TNFR1 (55, 56). (5) TNFR1 and TNFR2 have soluble forms (sTNFR1 and sTNFR2), whose activities and clinical implications are far from being fully resolved. It was suggested that at high concentrations the soluble receptors serve as sinks that reduce TNFα levels and thus inhibit its activities, while low levels of the soluble receptors enhance TNFα functions (57, 58), possibly through induction of reverse signaling following binding to mTNFα (27, 54, 59).
This very diverse array of molecular elements and events suggests that at particular settings, members of the network can lead to opposing effects. For instance, activation of TNFR1 by TNFα can lead to tumor cell death but under a different set of conditions it can contribute to cancer inflammation and enhance tumor progression. A similar enigma was observed for TNFR2+ tumor-infiltrating lymphocytes (TILs): TNFR2-mediated signals support the survival/activation of CD4+ T regulatory cells (Tregs) and aggravate disease course (46, 60–67); however, in triple-negative breast cancer (TNBC) patients, TNFR2+ TILs were associated with improved patient survival. In parallel, mouse studies have connected reduced TNBC growth after chemotherapy with elevated presence of CD8+ TNFR2+ TILs, presumably cytotoxic T cells (CTLs) (68, 69), agreeing with TNFR2 being required for cytotoxic activities of CD8+ T cells (66). Moreover, unlike several publications connecting TNFR2 expression by cancer cells to pro-tumor phenotypes (63, 70–72), TNFR2 was found to be protective in breast cancer, as demonstrated by using a mouse model with the loss of one of the TNFR2 alleles (73).
The balance and interactions between the different members of the TNFα-TNFR family – as well as their cross-talk with other factors of the TME and with different therapy modes – may dictate the path that this network takes in terms of cancer progression.
The TNFα-TNFR Road in Cancer Therapy – The Possible Inter-Connection Of the “ THERAPY” LANE AND THE “TARGET” LANE
The information obtained so far regarding the roles of TNFα and its receptors in cancer has split the scientific and clinical communities between those who consider TNFα as “therapy” and those who regard the different members of the TNFα-TNFR family as “targets”. In practice, it is possible that these two lanes of the TNFα-TNFR road are strongly connected to each other. For example, when TNFα fails to limit metastasis in a specific setting, this may be due to selection of cytotoxicity-resistant cells that also have acquired stronger pro-metastatic functions, such as increased invasiveness or production of angiogenic factors. Moreover, many reports have demonstrated that cells treated by TNFα acquired chemoresistance, endocrine resistance and reduced sensitivity to other therapy modes (27, 30, 47, 50, 74).
These observations connect the limited therapeutic potential of TNFα to selection of cancer cells that express improved pro-metastatic functions, leading to enhanced tumor progression. Thus, treating cancer patients with TNFα may eventually give rise to devastating metastasis-promoting effects, and may prove harmful rather than beneficial.
This scenario, and the strong evidence on the pro-metastatic roles of TNFα and its receptors in many cancer types, suggest that the pro-cancer and pro-metastatic functions of the TNFα-TNFR network dominate over their protective functions in malignancy. Supporting this possibility are many studies of patients suffering of autoimmune/inflammatory diseases, demonstrating that inhibition of the TNFα-TNFR pathway was not significantly associated with increased tumor risk or recurrence (with some, yet unsubstantiated, reservations regarding non-melanoma skin cancer and lymphoma) (75–81).
Taken together, the findings obtained so far suggest that when the TNFα-TNFR network is considered in cancer therapy, the “target” approach may apply better than the “therapy” tactic. Yet, to date, only a very limited number of clinical studies had analyzed the therapeutic value of TNFα-TNFR antagonists in cancer treatment. In several phase I and phase II trials, patients at locally advanced or metastatic stages of different malignant diseases were treated by antibodies against TNFα (infliximab) or soluble TNFR2 (etanercept). Partial or complete responses were noted only in a renal cell carcinoma study, but disease stabilization was observed in some of the patients in the other studies (82–85). In addition, a recent phase Ib clinical trial demonstrated relatively high response rates following the use of the TNFα inhibitor certolizumab together with anti-PD-1 and anti-CTLA-4 in melanoma patients (86).
Overall, as these clinical trials have been performed under unfavorable conditions – the cohort patients were at the most advanced stages of disease, and their immune system has been already manipulated by repeated therapies – their findings suggest that TNFα-TNFR-directed treatments may be effective in cancer. It is possible that if inhibitors of the TNFα-TNFR family members will be given the most optimal conditions to act, and if the targets will be carefully selected, better therapeutic indices could be achieved.
Discussion – The (Personalized) Road Ahead
To reach the aim of safe and effective use of TNFα-TNFR manipulations in cancer therapy, we need to consider the possibility that one type of TNFα-TNFR-directed therapy is not suitable to all cancer types and to all cancer patients; moreover, a specific therapy mode that applies to one cancer type/subtype may be detrimental in another.
Rather, the typical characteristics of tumor heterogeneity – inter-tumor and intra-tumor – call for a personalized approach that will carefully adjust the therapy mode and the treatment conditions to each malignancy type. First, it may be important to pre-select the patients who will most probably benefit from the modulation of TNFα-TNFR family members, and to start therapy as early as possible, to prevent the pro-metastatic activities of the network. For example, favorable candidates for treatment may be patients diagnosed at the early stage of breast ductal carcinoma in situ, whose tumors express TNFα (about half of the patients) (31).
Then, the roles of each family member should be precisely identified in each cancer type/subtype, prior to treating patients with modulators of the pathway. This can be well-exemplified by taking the TNFR2+ TIL population as a test case: the fact that unlike published reports on the Treg identify of CD4+ TNFR2+ lymphocytes (46, 60–67), TNFR2+ TILs were connected to improved survival in TNBC patients and with potential cytotoxic activities of CD8+ TNFR2+ TILs in mouse TNBC tumors (68, 69), suggests that targeting TNFR2 in chemotherapy-treated TNBC patients may be harmful; administration of TNFα inhibitors may reduce the proliferation of CD8+ TNFR2+ CTLs and limit the potential of raising potent immune activities against the cancer cells. The detrimental consequence that may be driven by such treatments may explain the findings obtained in TNFα-/- mice that could not mount T cell-mediated anti-tumor effects (87). Rather, the use of TNFR2 agonists (53, 54) may apply in order to promote the proliferation of cytotoxic CD8+ TNFR2+ TILs; alternatively, selective inhibitors of TNFR1 [(once clinically-approved (53, 54)] may be best suited in therapy as they may limit the chronic inflammation that is strongly induced by TNFα in the tumors.
Thus, when manipulation of members of the TNFα-TNFR family is considered in cancer therapy, one needs to determine many aspects in a most specific manner (Figure 1): who are the patients who can benefit from the treatment? Which TNFα-TNFR family member – in its membrane or soluble form – or its down-stream intracellular regulators, should be targeted? Do the various network members affect similarly different types of cells in a specific tumor type/subtype: cancer cells, endothelial cells, leukocytes and others? How TNFα activities are affected by other factors of the TME and regulate them [e.g., estrogen, EGF and TGFβ (30, 49, 50, 88, 89)]? Can TNFα-TNFR-directed therapies reach improved impacts when administered with other treatments, as reported recently to be the case with immune checkpoint blockades (86, 90, 91)?
Figure 1 Targeting members of the TNFα-TNFR family in cancer: The personalized road. The TNFα-TNFR network brings together complex interactions between the soluble and membrane forms of TNFα, as well as TNFR1 and TNFR2 with their diverse binding preferences to each of the TNFα forms, complex signaling cascades and soluble variants. This intricate system of ligands and receptors can lead to different consequences in various malignancies, raising the need to carefully identify specific players in each and every disease type, and possibly also in patients who were diagnosed with the same type of cancer. Thus, a personalized approach should be designed in order to establish the most appropriate and efficient therapeutic mode in cancer, vis-à-vis the use of modifiers of TNFα and its receptors. For example, the properties of one malignant disease (“Blue patients” in the Figure) in terms of TNFα-TNFR family members may considerably differ from the characteristics of another cancer type (“Orange patients”). To precisely identify who can benefit from treatments directed to any of the family members, it is necessary to determine the expression patterns of each partner in each patient; then, based on analyses of each malignancy and its subtypes, it is necessary to determine their roles in different disease stages, their impacts on different cell types in the tumor (cancer cells, endothelial cells, leukocytes, stromal cells), as well as their interactions with other TME factors and potential efficacy when combined with other cancer therapies. The information obtained by research of the different aspects and elements stands in the basis of a personalized approach that will target members of the TNFα-TNFR family or exploit them (e.g., by increasing the proportions/activities of beneficial TNFR2+ CD8+ TILs) that would reach an outmost efficacy in cancer therapy.
To conclude, the two seemingly opposing effects of the TNFα-TNFR network on cancer progression may be actually inter-connected, and eventually the pro-metastatic functions of the TNFα-TNFR family members possibly dominate their anti-malignancy effects. Moreover, the “one therapy mode suits all” approach in targeting the TNFα-TNFR pathway in cancer needs to be re-evaluated, and emphasis should be given to extensive research that will identify the most appropriate therapeutic mode for each malignancy type/subtype, in a specific and personalized manner.
Author Contributions
AB has designed the article, drafted all versions and is responsible for its contents.
Funding
Studies in the Ben-Baruch laboratory on the TNFα-TNFR network in cancer were supported during the last three years by DKFZ-MOST Cooperation in Cancer Research, Israel Cancer Research Fund, Federico Foundation and Israel Science Foundation.
Conflict of Interest
The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Acknowledgments
The author thanks the members of her team, at present and in the past, for their contribution to studies addressing the roles of TNFα-TNFR in cancer, that were performed in her laboratory.
References
1. Coley WB. the Treatment of Inoperable Sarcoma by Bacterial Toxins (the Mixed Toxins of the Streptococcus Erysipelas and the Bacillus Prodigiosus). Proc R Soc Med (1910) 3(Surg Sect):1–48. doi: 10.1177/003591571000301601
2. Balkwill F. Tumour Necrosis Factor and Cancer. Nat Rev Cancer (2009) 9(5):361–71. doi: 10.1038/nrc2628
3. Pennica D, Nedwin GE, Hayflick JS, Seeburg PH, Derynck R, Palladino MA, et al. Human Tumour Necrosis Factor: Precursor Structure, Expression and Homology to Lymphotoxin. Nature (1984) 312(5996):724–9. doi: 10.1038/312724a0
4. Marmenout A, Fransen L, Tavernier J, van der Heyden J, Tizard R, Kawashima E, et al. Molecular Cloning and Expression of Human Tumor Necrosis Factor and Comparison With Mouse Tumor Necrosis Factor. Eur J Biochem (1985) 152(3):515–22. doi: 10.1111/j.1432-1033.1985.tb09226.x
5. Loetscher H, Pan YC, Lahm HW, Gentz R, Brockhaus M, Tabuchi H, et al. Molecular Cloning and Expression of the Human 55 Kd Tumor Necrosis Factor Receptor. Cell (1990) 61(2):351–9. doi: 10.1016/0092-8674(90)90815-V
6. Schall TJ, Lewis M, Koller KJ, Lee A, Rice GC, Wong GH, et al. Molecular Cloning and Expression of a Receptor for Human Tumor Necrosis Factor. Cell (1990) 61(2):361–70. doi: 10.1016/0092-8674(90)90816-W
7. Heller RA, Song K, Onasch MA, Fischer WH, Chang D, Ringold GM. Complementary DNA Cloning of a Receptor for Tumor Necrosis Factor and Demonstration of a Shed Form of the Receptor. Proc Natl Acad Sci USA (1990) 87(16):6151–5. doi: 10.1073/pnas.87.16.6151
8. Smith CA, Davis T, Anderson D, Solam L, Beckmann MP, Jerzy R, et al. A Receptor for Tumor Necrosis Factor Defines an Unusual Family of Cellular and Viral Proteins. Science (1990) 248(4958):1019–23. doi: 10.1126/science.2160731
9. Brouckaert PG, Leroux-Roels GG, Guisez Y, Tavernier J, Fiers W. In Vivo Anti-Tumour Activity of Recombinant Human and Murine TNF, Alone and in Combination With Murine IFN-Gamma, on a Syngeneic Murine Melanoma. Int J Cancer (1986) 38(5):763–9. doi: 10.1002/ijc.2910380521
10. Balkwill FR, Lee A, Aldam G, Moodie E, Thomas JA, Tavernier J, et al. Human Tumor Xenografts Treated With Recombinant Human Tumor Necrosis Factor Alone or in Combination With Interferons. Cancer Res (1986) 46(8):3990–3.
11. Kircheis R, Ostermann E, Wolschek MF, Lichtenberger C, Magin-Lachmann C, Wightman L, et al. Tumor-Targeted Gene Delivery of Tumor Necrosis Factor-Alpha Induces Tumor Necrosis and Tumor Regression Without Systemic Toxicity. Cancer Gene Ther (2002) 9(8):673–80. doi: 10.1038/sj.cgt.7700487
12. Egeblad M, Jaattela M. Cell Death Induced by TNF or Serum Starvation is Independent of Erbb Receptor Signaling in MCF-7 Breast Carcinoma Cells. Int J Cancer (2000) 86(5):617–25. doi: 10.1002/(SICI)1097-0215(20000601)86:5<617::AID-IJC3>3.0.CO;2-Z
13. Simstein R, Burow M, Parker A, Weldon C, Beckman B. Apoptosis, Chemoresistance, and Breast Cancer: Insights From the MCF-7 Cell Model System. Exp Biol Med (Maywood) (2003) 228(9):995–1003. doi: 10.1177/153537020322800903
14. Zhou BP, Hu MC, Miller SA, Yu Z, Xia W, Lin SY, et al. HER-2/Neu Blocks Tumor Necrosis Factor-Induced Apoptosis via the Akt/NF-Kappab Pathway. J Biol Chem (2000) 275(11):8027–31. doi: 10.1074/jbc.275.11.8027
15. Roberts NJ, Zhou S, Diaz LA Jr, Holdhoff M. Systemic Use of Tumor Necrosis Factor Alpha as an Anticancer Agent. Oncotarget (2011) 2(10):739–51. doi: 10.18632/oncotarget.344
16. Verhoef C, de Wilt JH, Grunhagen DJ, van Geel AN, ten Hagen TL, Eggermont AM. Isolated Limb Perfusion With Melphalan and TNF-Alpha in the Treatment of Extremity Sarcoma. Curr Treat Options Oncol (2007) 8(6):417–27. doi: 10.1007/s11864-007-0044-y
17. Seynhaeve AL, Hoving S, Schipper D, Vermeulen CE, de Wiel-Ambagtsheer G, van Tiel ST, et al. Tumor Necrosis Factor Alpha Mediates Homogeneous Distribution of Liposomes in Murine Melanoma That Contributes to a Better Tumor Response. Cancer Res (2007) 67(19):9455–62. doi: 10.1158/0008-5472.CAN-07-1599
18. Bertazza LMS, DeWitte M, Nitti D eds. TNF and Cancer: Friends and/or Foes? Sharjah, United Arab Emirates: Bentham Science Publishers (2012).
19. Grunhagen DJ, de Wilt JH, Graveland WJ, Verhoef C, van Geel AN, Eggermont AM. Outcome and Prognostic Factor Analysis of 217 Consecutive Isolated Limb Perfusions With Tumor Necrosis Factor-Alpha and Melphalan for Limb-Threatening Soft Tissue Sarcoma. Cancer (2006) 106(8):1776–84. doi: 10.1002/cncr.21802
20. Runbeck E, Crescioli S, Karagiannis SN, Papa S. Utilizing Immunocytokines for Cancer Therapy. Antibodies (Basel) (2021) 10(1):10. doi: 10.3390/antib10010010
21. Weiss T, Puca E, Silginer M, Hemmerle T, Pazahr S, Bink A, et al. Immunocytokines Are a Promising Immunotherapeutic Approach Against Glioblastoma. Sci Transl Med (2020) 12(564):eabb2311. doi: 10.1126/scitranslmed.abb2311
22. Bauer S, Adrian N, Williamson B, Panousis C, Fadle N, Smerd J, et al. Targeted Bioactivity of Membrane-Anchored TNF by an Antibody-Derived TNF Fusion Protein. J Immunol (2004) 172(6):3930–9. doi: 10.4049/jimmunol.172.6.3930
23. Ziffels B, Pretto F, Neri D. Intratumoral Administration of IL2- and TNF-Based Fusion Proteins Cures Cancer Without Establishing Protective Immunity. Immunotherapy (2018) 10(3):177–88. doi: 10.2217/imt-2017-0119
24. Creagan ET, Kovach JS, Moertel CG, Frytak S, Kvols LK. A Phase I Clinical Trial of Recombinant Human Tumor Necrosis Factor. Cancer (1988) 62(12):2467–71. doi: 10.1002/1097-0142(19881215)62:12<2467::AID-CNCR2820621202>3.0.CO;2-5
25. Brown TD, Goodman P, Fleming T, Macdonald JS, Hersh EM, Braun TJ. A Phase II Trial of Recombinant Tumor Necrosis Factor in Patients With Adenocarcinoma of the Pancreas: A Southwest Oncology Group Study. J Immunother (1991) (1991) 10(5):376–8. doi: 10.1097/00002371-199110000-00010
26. Maccio A, Madeddu C. Inflammation and Ovarian Cancer. Cytokine (2012) 58(2):133–47. doi: 10.1016/j.cyto.2012.01.015
27. Mercogliano MF, Bruni S, Elizalde PV, Schillaci R. Tumor Necrosis Factor Alpha Blockade: An Opportunity to Tackle Breast Cancer. Front Oncol (2020) 10:584. doi: 10.3389/fonc.2020.00584
28. Powell IJ, Chinni SR, Reddy SS, Zaslavsky A, Gavande N. Pro-Inflammatory Cytokines and Chemokines Initiate Multiple Prostate Cancer Biologic Pathways of Cellular Proliferation, Heterogeneity and Metastasis in a Racially Diverse Population and Underlie the Genetic/Biologic Mechanism of Racial Disparity: Update. Urol Oncol (2021) 39(1):34–40. doi: 10.1016/j.urolonc.2020.08.019
29. Cruceriu D, Baldasici O, Balacescu O, Berindan-Neagoe I. The Dual Role of Tumor Necrosis Factor-Alpha (TNF-Alpha) in Breast Cancer: Molecular Insights and Therapeutic Approaches. Cell Oncol (Dordr) (2020) 43(1):1–18. doi: 10.1007/s13402-019-00489-1
30. Gong K, Guo G, Beckley N, Zhang Y, Yang X, Sharma M, et al. Tumor Necrosis Factor in Lung Cancer: Complex Roles in Biology and Resistance to Treatment. Neoplasia (2021) 23(2):189–96. doi: 10.1016/j.neo.2020.12.006
31. Soria G, Ofri-Shahak M, Haas I, Yaal-Hahoshen N, Leider-Trejo L, Leibovich-Rivkin T, et al. Inflammatory Mediators in Breast Cancer: Coordinated Expression of Tnfalpha & IL-1beta With CCL2 & CCL5 and Effects on Epithelial-to-Mesenchymal Transition. BMC Cancer (2011) 11:130. doi: 10.1186/1471-2407-11-130
32. Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancer-Related Inflammation, the Seventh Hallmark of Cancer: Links to Genetic Instability. Carcinogenesis (2009) 30(7):1073–81. doi: 10.1093/carcin/bgp127
33. Sethi G, Sung B, Aggarwal BB. TNF: A Master Switch for Inflammation to Cancer. Front Biosci (2008) 13:5094–107. doi: 10.2741/3066
34. Muthusami S, Ramachandran IK, Babu KN, Krishnamoorthy S, Guruswamy A, Queimado L, et al. Role of Inflammation in the Development of Colorectal Cancer. Endocr Metab Immune Disord Drug Targets (2021) 21(1):77–90. doi: 10.2174/1871530320666200909092908
35. Crusz SM, Balkwill FR. Inflammation and Cancer: Advances and New Agents. Nat Rev Clin Oncol (2015) 12(10):584–96. doi: 10.1038/nrclinonc.2015.105
36. Gupta M, Babic A, Beck AH, Terry K. TNF-Alpha Expression, Risk Factors, and Inflammatory Exposures in Ovarian Cancer: Evidence for an Inflammatory Pathway of Ovarian Carcinogenesis? Hum Pathol (2016) 54:82–91. doi: 10.1016/j.humpath.2016.03.006
37. Propper DJ, Balkwill FR. Harnessing Cytokines and Chemokines for Cancer Therapy. Nat Rev Clin Oncol (2022) 19:237–53. doi: 10.1038/s41571-021-00588-9
38. Galdiero MR, Marone G, Mantovani A. Cancer Inflammation and Cytokines. Cold Spring Harb Perspect Biol (2018) 10(8):a028662. doi: 10.1101/cshperspect.a028662
39. Miles DW, Happerfield LC, Naylor MS, Bobrow LG, Rubens RD, Balkwill FR. Expression of Tumour Necrosis Factor (TNF Alpha) and Its Receptors in Benign and Malignant Breast Tissue. Int J Cancer (1994) 56(6):777–82. doi: 10.1002/ijc.2910560603
40. Ben-Baruch A. The Tumor-Promoting Flow of Cells Into, Within and Out of the Tumor Site: Regulation by the Inflammatory Axis of Tnfalpha and Chemokines. Cancer Microenviron (2012) 5(2):151–64. doi: 10.1007/s12307-011-0094-3
41. Balkwill FR. The Chemokine System and Cancer. J Pathol (2012) 226(2):148–57. doi: 10.1002/path.3029
42. Hamaguchi T, Wakabayashi H, Matsumine A, Sudo A, Uchida A. TNF Inhibitor Suppresses Bone Metastasis in a Breast Cancer Cell Line. Biochem Biophys Res Commun (2011) 407(3):525–30. doi: 10.1016/j.bbrc.2011.03.051
43. Yu M, Zhou X, Niu L, Lin G, Huang J, Zhou W, et al. Targeting Transmembrane Tnf-Alpha Suppresses Breast Cancer Growth. Cancer Res (2013) 73(13):4061–74. doi: 10.1158/0008-5472.CAN-12-3946
44. Ji X, Peng Z, Li X, Yan Z, Yang Y, Qiao Z, et al. Neutralization of Tnfalpha in Tumor With a Novel Nanobody Potentiates Paclitaxel-Therapy and Inhibits Metastasis in Breast Cancer. Cancer Lett (2017) 386:24–34. doi: 10.1016/j.canlet.2016.10.031
45. Montfort A, Colacios C, Levade T, Andrieu-Abadie N, Meyer N, Segui B. The TNF Paradox in Cancer Progression and Immunotherapy. Front Immunol (2019) 10:1818. doi: 10.3389/fimmu.2019.01818
46. Jiang M, Liu J, Tross D, Li P, Chen F, Alam MM, et al. Chen X: A TNFR2 Antibody by Countering Immunosuppression Cooperates With HMGN1 and R848 Immune Stimulants to Inhibit Murine Colon Cancer. Int Immunopharmacol (2021) 101(Pt A):108345. doi: 10.1016/j.intimp.2021.108345
47. Baram T, Rubinstein-Achiasaf L, Ben-Yaakov H, Ben-Baruch A. Inflammation-Driven Breast Tumor Cell Plasticity: Stemness/EMT, Therapy Resistance and Dormancy. Front Oncol (2020) 10:614468. doi: 10.3389/fonc.2020.614468
48. Martinez-Reza I, Diaz L, Garcia-Becerra R. Preclinical and Clinical Aspects of TNF-Alpha and its Receptors TNFR1 and TNFR2 in Breast Cancer. J BioMed Sci (2017) 24(1):90. doi: 10.1186/s12929-017-0398-9
49. Ben-Baruch A. Partners in Crime: Tnfalpha-Based Networks Promoting Cancer Progression. Cancer Immunol Immunother (2020) 69(2):263–73. doi: 10.1007/s00262-019-02435-4
50. Weitzenfeld P, Meshel T, Ben-Baruch A. Microenvironmental Networks Promote Tumor Heterogeneity and Enrich for Metastatic Cancer Stem-Like Cells in Luminal-a Breast Tumor Cells. Oncotarget (2016) 7(49):81123–43. doi: 10.18632/oncotarget.13213
51. Shibue T, Weinberg RA. EMT, Cscs, and Drug Resistance: The Mechanistic Link and Clinical Implications. Nat Rev Clin Oncol (2017) 14(10):611–29. doi: 10.1038/nrclinonc.2017.44
52. Gough P, Myles IA. Tumor Necrosis Factor Receptors: Pleiotropic Signaling Complexes and Their Differential Effects. Front Immunol (2020) 11:585880. doi: 10.3389/fimmu.2020.585880
53. Fischer R, Kontermann RE, Pfizenmaier K. Selective Targeting of TNF Receptors as a Novel Therapeutic Approach. Front Cell Dev Biol (2020) 8:401. doi: 10.3389/fcell.2020.00401
54. Steeland S, Libert C, Vandenbroucke RE. A New Venue of TNF Targeting. Int J Mol Sci (2018) 19(5):1442. doi: 10.3390/ijms19051442
55. Naude PJ, den Boer JA, Luiten PG, Eisel UL. Tumor Necrosis Factor Receptor Cross-Talk. FEBS J (2011) 278(6):888–98. doi: 10.1111/j.1742-4658.2011.08017.x
56. Grell M, Zimmermann G, Gottfried E, Chen CM, Grunwald U, Huang DC, et al. : Induction of Cell Death by Tumour Necrosis Factor (TNF) Receptor 2, CD40 and CD30: A Role for TNF-R1 Activation by Endogenous Membrane-Anchored TNF. EMBO J (1999) 18(11):3034–43. doi: 10.1093/emboj/18.11.3034
57. Aderka D, Engelmann H, Maor Y, Brakebusch C, Wallach D. Stabilization of the Bioactivity of Tumor Necrosis Factor by its Soluble Receptors. J Exp Med (1992) 175(2):323–9. doi: 10.1084/jem.175.2.323
58. Van Zee KJ, Kohno T, Fischer E, Rock CS, Moldawer LL, Lowry SF. Tumor Necrosis Factor Soluble Receptors Circulate During Experimental and Clinical Inflammation and can Protect Against Excessive Tumor Necrosis Factor Alpha In Vitro and In Vivo. Proc Natl Acad Sci USA (1992) 89(11):4845–9. doi: 10.1073/pnas.89.11.4845
59. Qu Y, Zhao G, Li H. Forward and Reverse Signaling Mediated by Transmembrane Tumor Necrosis Factor-Alpha and TNF Receptor 2: Potential Roles in an Immunosuppressive Tumor Microenvironment. Front Immunol (2017) 8:1675. doi: 10.3389/fimmu.2017.01675
60. Vanamee ES, Faustman DL. TNFR2: A Novel Target for Cancer Immunotherapy. Trends Mol Med (2017) 23(11):1037–46. doi: 10.1016/j.molmed.2017.09.007
61. Chen X, Oppenheim JJ. Targeting TNFR2, an Immune Checkpoint Stimulator and Oncoprotein, is a Promising Treatment for Cancer. Sci Signaling (2017) 10(462):eaal2328. doi: 10.1126/scisignal.aal2328
62. Chen X, Baumel M, Mannel DN, Howard OM, Oppenheim JJ. Interaction of TNF With TNF Receptor Type 2 Promotes Expansion and Function of Mouse CD4+CD25+ T Regulatory Cells. J Immunol (2007) 179(1):154–61. doi: 10.4049/jimmunol.179.1.154
63. Torrey H, Butterworth J, Mera T, Okubo Y, Wang L, Baum D, et al. Targeting TNFR2 With Antagonistic Antibodies Inhibits Proliferation of Ovarian Cancer Cells and Tumor-Associated Tregs. Sci Signaling (2017) 10(462):eaaf8608. doi: 10.1126/scisignal.aaf8608
64. He J, Li R, Chen Y, Hu Y, Chen X. TNFR2-Expressing CD4(+)Foxp3(+) Regulatory T Cells in Cancer Immunology and Immunotherapy. Prog Mol Biol Transl Sci (2019) 164:101–17. doi: 10.1016/bs.pmbts.2019.03.010
65. Chen X, Hamano R, Subleski JJ, Hurwitz AA, Howard OM, Oppenheim JJ. Expression of Costimulatory TNFR2 Induces Resistance of CD4+Foxp3- Conventional T Cells to Suppression by CD4+Foxp3+ Regulatory T Cells. J Immunol (2010) 185(1):174–82. doi: 10.4049/jimmunol.0903548
66. Ye LL, Wei XS, Zhang M, Niu YR, Zhou Q. The Significance of Tumor Necrosis Factor Receptor Type II in CD8(+) Regulatory T Cells and CD8(+) Effector T Cells. Front Immunol (2018) 9:583. doi: 10.3389/fimmu.2018.00583
67. Qu Y, Wang X, Bai S, Niu L, Zhao G, Yao Y, et al. The Effects of TNF-Alpha/TNFR2 in Regulatory T Cells on the Microenvironment and Progression of Gastric Cancer. Int J Cancer (2022) 150(8):1373–91. doi: 10.1002/ijc.33873
68. Baram T, Erlichman N, Dadiani M, Balint-Lahat N, Pavlovski A, Morzaev-Sulzbach D, et al. Chemotherapy Shifts the Balance in Favor of CD8+ TNFR2+ Tils in Triple-Negative Breast Tumors. Cells (2021) 10:1429. doi: 10.3390/cells10061429
69. Dadiani M, Necula D, Kahana-Edwin S, Oren N, Baram T, Marin I, et al. TNFR2+ Tils are Significantly Associated With Improved Survival in Triple-Negative Breast Cancer Patients. Cancer Immunol Immunother (2020) 69(7):1315–26. doi: 10.1007/s00262-020-02549-0
70. Yang F, Zhao N, Wu N. TNFR2 Promotes Adriamycin Resistance in Breast Cancer Cells by Repairing DNA Damage. Mol Med Rep (2017) 16(3):2962–8. doi: 10.3892/mmr.2017.6898
71. Torrey H, Khodadoust M, Tran L, Baum D, Defusco A, Kim YH, et al. Targeted Killing of TNFR2-Expressing Tumor Cells and Tregs by TNFR2 Antagonistic Antibodies in Advanced Sezary Syndrome. Leukemia (2019) 33(5):1206–18. doi: 10.1038/s41375-018-0292-9
72. Bradley JR, Wang J, Pacey S, Warren AY, Pober JS, Al-Lamki RS. Tumor Necrosis Factor Receptor-2 Signaling Pathways Promote Survival of Cancer Stem-Like CD133(+) Cells in Clear Cell Renal Carcinoma. FASEB Bioadv (2020) 2(2):126–44. doi: 10.1096/fba.2019-00071
73. He L, Bhat K, Duhacheck-Muggy S, Ioannidis A, Zhang L, Nguyen NT, et al. Tumor Necrosis Factor Receptor Signaling Modulates Carcinogenesis in a Mouse Model of Breast Cancer. Neoplasia (2021) 23(2):197–209. doi: 10.1016/j.neo.2020.12.007
74. Antoon JW, Lai R, Struckhoff AP, Nitschke AM, Elliott S, Martin EC, et al. Altered Death Receptor Signaling Promotes Epithelial-to-Mesenchymal Transition and Acquired Chemoresistance. Sci Rep (2012) 2:539. doi: 10.1038/srep00539
75. Huss V, Bower H, Wadstrom H, Frisell T, Askling J. Group a: Short- and Longer-Term Cancer Risks With Biologic and Targeted Synthetic Disease Modifying Antirheumatic Drugs as Used Against Rheumatoid Arthritis in Clinical Practice. Rheumatol (Oxford) (2021), keab570. doi: 10.1093/rheumatology/keab570
76. Hellgren K, Ballegaard C, Delcoigne B, Cordtz R, Nordstrom D, Aaltonen K, et al. Risk of Solid Cancers Overall and by Subtypes in Patients With Psoriatic Arthritis Treated With TNF Inhibitors - A Nordic Cohort Study. Rheumatol (Oxford) (2021) 60(8):3656–68. doi: 10.1093/rheumatology/keaa828
77. Chen Y, Friedman M, Liu G, Deodhar A, Chu CQ. Do Tumor Necrosis Factor Inhibitors Increase Cancer Risk in Patients With Chronic Immune-Mediated Inflammatory Disorders? Cytokine (2018) 101:78–88. doi: 10.1016/j.cyto.2016.09.013
78. Raaschou P, Soderling J, Turesson C, Askling J, Group AS. Tumor Necrosis Factor Inhibitors and Cancer Recurrence in Swedish Patients With Rheumatoid Arthritis: A Nationwide Population-Based Cohort Study. Ann Intern Med (2018) 169(5):291–9. doi: 10.7326/M17-2812
79. Askling J, Fored CM, Baecklund E, Brandt L, Backlin C, Ekbom A, et al. Haematopoietic Malignancies in Rheumatoid Arthritis: Lymphoma Risk and Characteristics After Exposure to Tumour Necrosis Factor Antagonists. Ann Rheum Dis (2005) 64(10):1414–20. doi: 10.1136/ard.2004.033241
80. Mercer LK, Regierer AC, Mariette X, Dixon WG, Baecklund E, Hellgren K, et al. Spectrum of Lymphomas Across Different Drug Treatment Groups in Rheumatoid Arthritis: A European Registries Collaborative Project. Ann Rheum Dis (2017) 76(12):2025–30. doi: 10.1136/annrheumdis-2017-211623
81. Baecklund E, Askling J, Rosenquist R, Ekbom A, Klareskog L. Rheumatoid Arthritis and Malignant Lymphomas. Curr Opin Rheumatol (2004) 16(3):254–61. doi: 10.1097/00002281-200405000-00014
82. Madhusudan S, Foster M, Muthuramalingam SR, Braybrooke JP, Wilner S, Kaur K, et al. A Phase II Study of Etanercept (Enbrel), A Tumor Necrosis Factor Alpha Inhibitor in Patients With Metastatic Breast Cancer. Clin Cancer Res (2004) 10(19):6528–34. doi: 10.1158/1078-0432.CCR-04-0730
83. Madhusudan S, Muthuramalingam SR, Braybrooke JP, Wilner S, Kaur K, Han C, et al. Study of Etanercept, a Tumor Necrosis Factor-Alpha Inhibitor, in Recurrent Ovarian Cancer. J Clin Oncol (2005) 23(25):5950–9. doi: 10.1200/JCO.2005.04.127
84. Brown ER, Charles KA, Hoare SA, Rye RL, Jodrell DI, Aird RE, et al. A Clinical Study Assessing the Tolerability and Biological Effects of Infliximab, A TNF-Alpha Inhibitor, in Patients With Advanced Cancer. Ann Oncol (2008) 19(7):1340–6. doi: 10.1093/annonc/mdn054
85. Harrison ML, Obermueller E, Maisey NR, Hoare S, Edmonds K, Li NF, et al. Tumor Necrosis Factor Alpha as a New Target for Renal Cell Carcinoma: Two Sequential Phase II Trials of Infliximab at Standard and High Dose. J Clin Oncol (2007) 25(29):4542–9. doi: 10.1200/JCO.2007.11.2136
86. Montfort A, Filleron T, Virazels M, Dufau C, Milhes J, Pages C, et al. Combining Nivolumab and Ipilimumab With Infliximab or Certolizumab in Patients With Advanced Melanoma: First Results of a Phase Ib Clinical Trial. Clin Cancer Res (2021) 27(4):1037–47. doi: 10.1158/1078-0432.CCR-20-3449
87. Baxevanis CN, Voutsas IF, Tsitsilonis OE, Tsiatas ML, Gritzapis AD, Papamichail M. Compromised Anti-Tumor Responses in Tumor Necrosis Factor-Alpha Knockout Mice. Eur J Immunol (2000) 30(7):1957–66. doi: 10.1002/1521-4141(200007)30:7<1957::AID-IMMU1957>3.0.CO;2-7
88. Li Y, Zhu G, Zhai H, Jia J, Yang W, Li X, et al. Simultaneous Stimulation With Tumor Necrosis Factor-Alpha and Transforming Growth Factor-Beta1 Induces Epithelial-Mesenchymal Transition in Colon Cancer Cells via the NF-Kappab Pathway. Oncol Lett (2018) 15(5):6873–80. doi: 10.3892/ol.2018.8230
89. Weitzenfeld P, Kossover O, Korner C, Meshel T, Wiemann S, Seliktar D, et al. Chemokine Axes in Breast Cancer: Factors of the Tumor Microenvironment Reshape the CCR7-Driven Metastatic Spread of Luminal-a Breast Tumors. J Leukoc Biol (2016) 99(6):1009–25. doi: 10.1189/jlb.3MA0815-373R
90. Case K, Tran L, Yang M, Zheng H, Kuhtreiber WM, Faustman DL. TNFR2 Blockade Alone or in Combination With PD-1 Blockade Shows Therapeutic Efficacy in Murine Cancer Models. J Leukoc Biol (2020) 107(6):981–91. doi: 10.1002/JLB.5MA0420-375RRRRR
Keywords: cancer, personalized therapy, tumor necrosis factor α/TNFα, TNFR1, TNFR2
Citation: Ben-Baruch A (2022) Tumor Necrosis Factor α: Taking a Personalized Road in Cancer Therapy. Front. Immunol. 13:903679. doi: 10.3389/fimmu.2022.903679
Received: 24 March 2022; Accepted: 25 April 2022;
Published: 18 May 2022.
Edited by:
Marcus Thelen, Institute for Research in Biomedicine (IRB), SwitzerlandReviewed by:
Samuele Cazzamalli, Philochem, SwitzerlandCarsten Riether, Bern University Hospital, Switzerland
Copyright © 2022 Ben-Baruch. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Adit Ben-Baruch, aditbb@tauex.tau.ac.il